A Phase 1 interventional study of gemigliptin 50mg, rosuvastatin 20mg in Healthy, sponsored by LG Life Sciences. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-11.
Sponsored by LG Life Sciences (part of LG Chem) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.
This study is to evaluate the safety/tolerability and pharmacokinetics(AUC and Cmax) of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.
LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.
First submitted before LG Life Sciences became part of LG Chem.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Coadministration of gemigliptin 50mg and rosuvastatin 20mg
Drug: gemigliptin 50mg, rosuvastatin 20mg
Combination of gemigliptin 50mg / rosuvastatin 20mg
Drug: gemigliptin 50mg, rosuvastatin 20mg
gemigliptin/rosuvastatin 50/20mg
Also known as: Zemiglo, Cresto
AUClast, Cmax
To evaluate AUClast/Cmax of gemigliptin and rosuvastatin
Time frame: up to 72h post-dose
AUCinf
To evaluate AUCinf of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin
Time frame: up to 72h post-dose
Tmax
To evaluate Tmax of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin
Time frame: up to 72h post-dose
t1/2
To evaluate t1/2 of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin
Time frame: up to 72h post-dose
CL/F
To evaluate CL/F of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin
Time frame: up to 72h post-dose
metabolic ratio
To evaluate metabolic ratio of gemigliptin, LC15-0636 of gemigliptin metabolite
Time frame: up to 72h post-dose
AUEC
This parameter is been used to measure pharmarcodynamic characters of gemigliptin, the supression rate of DPP4 activity.
Time frame: up to 72h post-dose
Emax
This parameter is been used to measure pharmarcodynamic characters of gemigliptin, the supression rate of DPP4 activity.
Time frame: up to 72h post-dose
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Mar 2016, a primary completion of Apr 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemigliptin